Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of Amatuximab in Combination With Pemetrexed and Cisplatin in Subjects With Unresectable Malignant Pleural Mesothelioma

NCT02357147 is registered in ClinicalTrials.gov with Morphotek as lead sponsor.

NCT NCT02357147
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02357147 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of Amatuximab in Combination With Pemetrexed and Cisplatin in Subjects With Unresectable Malignant Pleural Mesothelioma
Lead sponsor
Morphotek
Phase
Phase 2
Overall status
Terminated
Start date
November 3, 2015
Completion date
November 30, 2018
Enrollment
124 (actual)
Sites
49

Conditions

As the registry lists them; a condition with its own page is linked.

mesothelioma, malignant